Glyphic Biotechnologies, Nutrible, and MabSwitch, Inc Named Awardees in CLS Inspire QuickFire Challenge for Diverse InnovatorsBack
SOUTH SAN FRANCISCO, Calif. — California Life Sciences (CLS), together with Johnson & Johnson Innovation, AbbVie and 5AM Ventures, announced today that Glyphic Biotechnologies, Nutrible, and MabSwitch, Inc have been selected as the awardees in CLSA Inspire QuickFire Challenge for Diverse Innovators.
To help advance their research, the three awardees will receive $50,000 each in grant funding from California Life Sciences’ (CLS) Racial and Social Equity Initiative.
Glyphic Biotechnologies is a biotechnology startup that is developing a single-molecule protein sequencing platform that aims to increase binding affinity and improve consistency to help create personalized, precision cancer vaccines for patients of all backgrounds.
Nutrible is a virtual registered dietitian platform that seeks to be a one-stop-shop in the fight against food deserts by providing nutrition education and delivering healthy food directly to patients who need it most.
MabSwitch, Inc is a biotechnology company that aims to develop regulatable next generation immunotherapies based on a proprietary universal allosteric switch module for antibodies (UNASMA) technology platform to address diseases of significant unmet medical need.
In addition, Glyphic will become the first Spring 2022 QuickFire Challenge-FAST-track company, receiving 12 hours of advisory services from an experienced group of industry veterans to advance its commercialization strategy
The QuickFire Challenges are managed by Johnson & Johnson Innovation, with the goal to help address today’s greatest health care challenges.
About California Life Sciences (CLS)
California Life Sciences (CLS) is the state’s most influential and impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For more than 30 years, CLS has served the community by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. As integral components of a healthy and collaborative ecosystem, CLS also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. With offices in South San Francisco, San Diego, Sacramento, Los Angeles, and Washington DC, CLS works to shape public policy, improve access to breakthrough technologies, educate lawmakers, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. In doing so, CLS fulfills its mission to protect and nurture California’s life sciences industry, empowering discoveries that lead to healthier lives around the world. Visit CLS at www.califesciences.org, and follow us on Twitter @CALifeSciences, Facebook, LinkedIn and YouTube.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn
About 5AM Ventures
Founded in 2002, 5AM actively invests in next-generation biotech companies. With approximately $1.5 billion raised since inception, 5AM has invested in 73 companies including Arvinas (NASDAQ: ARVN), Audentes Therapeutics (NASDAQ: BOLD), Crinetics Pharmaceuticals (NASDAQ: CRNX), DVS Sciences (acquired by Fluidigm), Envoy Therapeutics (acquired by Takeda), Flexion Therapeutics (NASDAQ: FLXN), Homology Medicines (NASDAQ: FIXX), Ikaria (acquired by Mallinckrodt), Ilypsa (acquired by Amgen), Marcadia Biotech (acquired by Roche), Novira Therapeutics (acquired by J&J), Pearl Therapeutics (acquired by AstraZeneca) and Relypsa (acquired by Vifor Pharma). For more information, please visit www.5amventures.com.